Trade Sana Biotechnology, Inc. - SANA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Sana Biotechnology Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 3.87 |
| Open* | 3.84 |
| 1-Year Change* | -14.09% |
| Day's Range* | 3.69 - 3.91 |
| 52 wk Range | 2.75-8.01 |
| Average Volume (10 days) | 1.42M |
| Average Volume (3 months) | 27.10M |
| Market Cap | 790.50M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 197.13M |
| Revenue | N/A |
| EPS | -1.44 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Mar 14, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 8, 2023 | 3.69 | -0.22 | -5.63% | 3.91 | 3.91 | 3.69 |
| Dec 7, 2023 | 3.87 | 0.06 | 1.57% | 3.81 | 3.93 | 3.81 |
| Dec 6, 2023 | 3.82 | -0.19 | -4.74% | 4.01 | 4.07 | 3.82 |
| Dec 5, 2023 | 3.98 | 0.09 | 2.31% | 3.89 | 4.17 | 3.83 |
| Dec 4, 2023 | 4.05 | 0.13 | 3.32% | 3.92 | 4.07 | 3.49 |
| Dec 1, 2023 | 4.01 | -0.01 | -0.25% | 4.02 | 4.09 | 3.74 |
| Nov 30, 2023 | 4.02 | -0.22 | -5.19% | 4.24 | 4.37 | 3.97 |
| Nov 29, 2023 | 4.15 | -0.08 | -1.89% | 4.23 | 4.37 | 4.08 |
| Nov 28, 2023 | 4.21 | 0.07 | 1.69% | 4.14 | 4.34 | 4.13 |
| Nov 27, 2023 | 4.21 | -0.02 | -0.47% | 4.23 | 4.31 | 4.12 |
| Nov 24, 2023 | 4.30 | 0.06 | 1.42% | 4.24 | 4.42 | 4.19 |
| Nov 22, 2023 | 4.22 | 0.21 | 5.24% | 4.01 | 4.27 | 4.01 |
| Nov 21, 2023 | 3.99 | -0.15 | -3.62% | 4.14 | 4.22 | 3.98 |
| Nov 20, 2023 | 4.28 | 0.09 | 2.15% | 4.19 | 4.48 | 4.13 |
| Nov 17, 2023 | 4.17 | 0.21 | 5.30% | 3.96 | 4.25 | 3.87 |
| Nov 16, 2023 | 3.90 | -0.23 | -5.57% | 4.13 | 4.19 | 3.82 |
| Nov 15, 2023 | 4.22 | 0.43 | 11.35% | 3.79 | 4.37 | 3.79 |
| Nov 14, 2023 | 3.79 | 0.11 | 2.99% | 3.68 | 3.86 | 3.66 |
| Nov 13, 2023 | 3.46 | 0.17 | 5.17% | 3.29 | 3.49 | 3.22 |
| Nov 10, 2023 | 3.34 | 0.05 | 1.52% | 3.29 | 3.34 | 3.04 |
Sana Biotechnology, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, March 14, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Sana Biotechnology Inc Earnings Release Q4 2023 Sana Biotechnology Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 272.564 | 356.909 | 286.149 | 141.152 | 13.246 |
| Selling/General/Admin. Expenses, Total | 71.561 | 50.41 | 27.77 | 21.177 | 4.206 |
| Research & Development | 285.885 | 248.626 | 257.879 | 119.375 | 9.04 |
| Operating Income | -272.564 | -356.909 | -286.149 | -141.152 | -13.246 |
| Interest Income (Expense), Net Non-Operating | 3.762 | 0.676 | 0.747 | 2.856 | 0 |
| Other, Net | -0.674 | 0.305 | 0.097 | -0.029 | -0.001 |
| Net Income Before Taxes | -269.476 | -355.928 | -285.305 | -138.325 | -13.247 |
| Net Income After Taxes | -269.476 | -355.928 | -285.305 | -130.778 | -13.247 |
| Net Income Before Extra. Items | -269.476 | -355.928 | -285.305 | -130.778 | -13.247 |
| Net Income | -269.476 | -355.928 | -285.305 | -130.778 | -13.247 |
| Income Available to Common Excl. Extra. Items | -269.476 | -355.928 | -285.305 | -130.778 | -13.247 |
| Income Available to Common Incl. Extra. Items | -269.476 | -355.928 | -285.305 | -130.778 | -13.247 |
| Diluted Net Income | -269.476 | -355.928 | -285.305 | -130.778 | -13.247 |
| Diluted Weighted Average Shares | 188.344 | 166.433 | 183.815 | 183.815 | 183.815 |
| Diluted EPS Excluding Extraordinary Items | -1.43076 | -2.13857 | -1.55213 | -0.71147 | -0.07207 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -1.43076 | -2.13857 | -1.54941 | -0.70934 | -0.07207 |
| Unusual Expense (Income) | 0.5 | 0.6 | |||
| Other Operating Expenses, Total | -84.882 | 57.873 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 116.289 | 84.052 | 81.788 | 86.187 | 72.904 |
| Selling/General/Admin. Expenses, Total | 16.566 | 16.766 | 23.321 | 15.514 | 18.292 |
| Research & Development | 73.044 | 67.166 | 63.921 | 76.735 | 72.54 |
| Other Operating Expenses, Total | 26.679 | 0.12 | -5.454 | -6.062 | -17.928 |
| Operating Income | -116.289 | -84.052 | -81.788 | -86.187 | -72.904 |
| Interest Income (Expense), Net Non-Operating | 2.374 | 1.976 | 1.613 | 1.173 | 0.637 |
| Other, Net | -0.084 | -0.047 | -0.268 | -0.106 | -0.198 |
| Net Income Before Taxes | -113.999 | -82.123 | -80.443 | -85.12 | -72.465 |
| Net Income After Taxes | -113.999 | -82.123 | -80.443 | -85.12 | -72.465 |
| Net Income Before Extra. Items | -113.999 | -82.123 | -80.443 | -85.12 | -72.465 |
| Net Income | -113.999 | -82.123 | -80.443 | -85.12 | -72.465 |
| Total Adjustments to Net Income | |||||
| Income Available to Common Excl. Extra. Items | -113.999 | -82.123 | -80.443 | -85.12 | -72.465 |
| Income Available to Common Incl. Extra. Items | -113.999 | -82.123 | -80.443 | -85.12 | -72.465 |
| Diluted Net Income | -113.999 | -82.123 | -80.443 | -85.12 | -72.465 |
| Diluted Weighted Average Shares | 192.54 | 191.228 | 190.441 | 189.303 | 187.626 |
| Diluted EPS Excluding Extraordinary Items | -0.59208 | -0.42945 | -0.4224 | -0.44965 | -0.38622 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.59208 | -0.42945 | -0.4224 | -0.44965 | -0.38622 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 444.437 | 558.101 | 384.467 | 144.263 | 32.596 |
| Cash and Short Term Investments | 423.963 | 550.996 | 378.264 | 138.982 | 30.63 |
| Cash & Equivalents | 176.765 | 253.029 | 124.806 | 80.03 | 30.63 |
| Short Term Investments | 247.198 | 297.967 | 253.458 | 58.952 | 0 |
| Prepaid Expenses | 14.374 | 7.105 | 6.203 | 5.281 | 1.966 |
| Total Assets | 822.72 | 1129.41 | 730.296 | 415.192 | 34.333 |
| Property/Plant/Equipment, Total - Net | 159.403 | 161.784 | 109.943 | 68.808 | 0.585 |
| Property/Plant/Equipment, Total - Gross | 193.38 | 180.558 | 117.68 | 70.624 | 0.586 |
| Accumulated Depreciation, Total | -33.977 | -18.774 | -7.737 | -1.816 | -0.001 |
| Goodwill, Net | 140.627 | 140.627 | 140.627 | 140.627 | 0 |
| Intangibles, Net | 59.195 | 59.195 | 59.195 | 59.195 | 0 |
| Other Long Term Assets, Total | 9.007 | 13.819 | 2.333 | 2.299 | 1.152 |
| Total Current Liabilities | 111.504 | 99.235 | 31.451 | 19.323 | 1.785 |
| Accounts Payable | 2.857 | 2.219 | 2.253 | 0 | 0.289 |
| Accrued Expenses | 50.436 | 38.246 | 25.538 | 17.69 | 1.132 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 58.211 | 58.77 | 3.66 | 1.633 | 0.364 |
| Total Liabilities | 323.405 | 400.905 | 298.583 | 140.375 | 1.8 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 211.901 | 301.67 | 267.132 | 121.052 | 0.015 |
| Total Equity | 499.315 | 728.502 | 431.713 | 274.817 | 32.533 |
| Redeemable Preferred Stock | 0 | 0 | 926.666 | 450.837 | 46.536 |
| Preferred Stock - Non Redeemable, Net | -73.769 | -33.478 | -0.815 | ||
| Common Stock | 0.019 | 0.018 | 0.002 | 0.001 | 0.001 |
| Additional Paid-In Capital | 1558.46 | 1515.21 | 8.216 | 1.558 | 0.058 |
| Retained Earnings (Accumulated Deficit) | -1054.84 | -785.36 | -429.432 | -144.127 | -13.247 |
| Other Equity, Total | -4.327 | -1.366 | 0.03 | 0.026 | 0 |
| Total Liabilities & Shareholders’ Equity | 822.72 | 1129.41 | 730.296 | 415.192 | 34.333 |
| Total Common Shares Outstanding | 191.022 | 184.929 | 183.815 | 183.815 | 183.815 |
| Long Term Investments | 10.051 | 195.881 | 33.731 | 0 | |
| Other Current Assets, Total | 6.1 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 279.522 | 338.621 | 369.908 | 444.437 | 500.25 |
| Cash and Short Term Investments | 268.57 | 325.915 | 349.306 | 423.963 | 485.75 |
| Cash & Equivalents | 168.448 | 173.787 | 160.456 | 176.765 | 163.343 |
| Short Term Investments | 100.122 | 152.128 | 188.85 | 247.198 | 322.407 |
| Prepaid Expenses | 7.12 | 6.606 | 14.502 | 14.374 | 8.4 |
| Total Assets | 631.44 | 707.147 | 746.928 | 822.72 | 898.102 |
| Property/Plant/Equipment, Total - Net | 145.604 | 157.369 | 162.376 | 159.403 | 163.082 |
| Property/Plant/Equipment, Total - Gross | 192.87 | 200.139 | 200.699 | 193.38 | 193.278 |
| Accumulated Depreciation, Total | -47.266 | -42.77 | -38.323 | -33.977 | -30.196 |
| Goodwill, Net | 140.627 | 140.627 | 140.627 | 140.627 | 140.627 |
| Intangibles, Net | 59.195 | 59.195 | 59.195 | 59.195 | 59.195 |
| Long Term Investments | 0 | 0 | 5.825 | 10.051 | 25.823 |
| Other Long Term Assets, Total | 6.492 | 11.335 | 8.997 | 9.007 | 9.125 |
| Total Current Liabilities | 66.644 | 112.105 | 102.777 | 111.504 | 114.813 |
| Accounts Payable | 9.928 | 3.089 | 2.334 | 2.857 | 3.993 |
| Accrued Expenses | 54.645 | 47.175 | 40.981 | 50.436 | 49.143 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 2.071 | 61.841 | 59.462 | 58.211 | 61.677 |
| Total Liabilities | 265.588 | 352.118 | 318.666 | 323.405 | 332.083 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 198.944 | 240.013 | 215.889 | 211.901 | 217.27 |
| Total Equity | 365.852 | 355.029 | 428.262 | 499.315 | 566.019 |
| Common Stock | 0.02 | 0.02 | 0.019 | 0.019 | 0.019 |
| Additional Paid-In Capital | 1616.01 | 1606.83 | 1567.34 | 1558.46 | 1546.81 |
| Retained Earnings (Accumulated Deficit) | -1249.97 | -1250.96 | -1136.96 | -1054.84 | -974.393 |
| Unrealized Gain (Loss) | |||||
| Total Liabilities & Shareholders’ Equity | 631.44 | 707.147 | 746.928 | 822.72 | 898.102 |
| Total Common Shares Outstanding | 197.064 | 196.88 | 191.409 | 191.022 | 189.885 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Other Equity, Total | -0.202 | -0.865 | -2.139 | -4.327 | -6.414 |
| Other Current Assets, Total | 3.832 | 6.1 | 6.1 | 6.1 | 6.1 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -269.476 | -355.928 | -285.305 | -130.778 | -13.247 |
| Cash From Operating Activities | -290.05 | -251.054 | -137.982 | -85.518 | -13.495 |
| Cash From Operating Activities | 15.625 | 11.07 | 5.921 | 1.826 | 0.001 |
| Deferred Taxes | 0 | 0 | -7.547 | 0 | |
| Non-Cash Items | -43.741 | 84.003 | 135.246 | 40.469 | 0.059 |
| Changes in Working Capital | 7.542 | 9.801 | 6.156 | 10.512 | -0.308 |
| Cash From Investing Activities | 210.562 | -245.798 | -252.563 | -87.861 | -0.78 |
| Capital Expenditures | -20.876 | -29.862 | -23.872 | -26.124 | -0.46 |
| Other Investing Cash Flow Items, Total | 231.438 | -215.936 | -228.691 | -61.737 | -0.32 |
| Cash From Financing Activities | 4.913 | 631.751 | 435.687 | 223.74 | 45.721 |
| Financing Cash Flow Items | 0 | 0 | |||
| Issuance (Retirement) of Stock, Net | 4.913 | 631.751 | 435.687 | 223.74 | 45.721 |
| Net Change in Cash | -74.575 | 134.899 | 45.142 | 50.361 | 31.446 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -82.123 | -269.476 | -189.033 | -103.913 | -31.448 |
| Cash From Operating Activities | -79.272 | -290.05 | -213.983 | -149.187 | -77.709 |
| Cash From Operating Activities | 4.346 | 15.625 | 11.43 | 7.414 | 3.614 |
| Non-Cash Items | 9.312 | -43.741 | -49.51 | -53.744 | -46.514 |
| Changes in Working Capital | -10.807 | 7.542 | 13.13 | 1.056 | -3.361 |
| Cash From Investing Activities | 62.727 | 210.562 | 122.134 | 90.275 | 12.545 |
| Capital Expenditures | -2.176 | -20.876 | -16.274 | -11.924 | -7.533 |
| Other Investing Cash Flow Items, Total | 64.903 | 231.438 | 138.408 | 102.199 | 20.078 |
| Cash From Financing Activities | 0.236 | 4.913 | 3.852 | 2.231 | 0.652 |
| Issuance (Retirement) of Stock, Net | 0.236 | 4.913 | 3.852 | 2.231 | 0.652 |
| Net Change in Cash | -16.309 | -74.575 | -87.997 | -56.681 | -64.512 |
| Deferred Taxes |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | 22.3632 | 44042500 | 0 | 2022-12-31 | LOW |
| Flagship Ventures | Venture Capital | 10.9214 | 21508743 | -11781275 | 2023-09-13 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 8.4512 | 16644065 | 6938967 | 2023-06-30 | LOW |
| Baillie Gifford & Co. | Investment Advisor | 5.5022 | 10836161 | -40768 | 2023-06-30 | LOW |
| CPP Investment Board | Pension Fund | 5.1665 | 10175000 | 0 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.5923 | 9044136 | -25514 | 2023-06-30 | LOW |
| Harr (Steven D) | Individual Investor | 4.4969 | 8856250 | 0 | 2023-04-03 | |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.4156 | 6726670 | 141372 | 2023-06-30 | LOW |
| Bishop (Hans Edgar) | Individual Investor | 2.9308 | 5771965 | 6925 | 2023-10-05 | LOW |
| PSP Investments | Pension Fund | 2.7273 | 5371293 | -1028707 | 2023-06-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 2.5809 | 5082849 | 618520 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.4565 | 4837803 | -855577 | 2023-06-30 | LOW |
| Crestline Investors, Inc. | Hedge Fund | 1.7089 | 3365624 | 154687 | 2023-06-30 | HIGH |
| Mulligan (Richard Charles PH.D) | Individual Investor | 1.5223 | 2998121 | 0 | 2023-04-03 | LOW |
| Alphabet, Inc. | Venture Capital | 1.4281 | 2812500 | 0 | 2023-06-30 | LOW |
| Suvretta Capital Management, LLC | Hedge Fund | 1.0733 | 2113800 | 0 | 2023-06-30 | HIGH |
| Baker Bros. Advisors LP | Hedge Fund | 1.0155 | 2000000 | 0 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0067 | 1982530 | 201565 | 2023-06-30 | LOW |
| Capital Research Global Investors | Investment Advisor | 0.9969 | 1963378 | 0 | 2023-09-30 | LOW |
| Agarwal (Sunil) | Individual Investor | 0.787 | 1550000 | 0 | 2023-04-03 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sana Biotechnology, Inc. Company profile
About Sana Biotechnology Inc
Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Sana Biotechnology Inc revenues was not reported. Net loss increased 42% to $245.2M. Higher net loss reflects Personnel increase of 36% to $55.2M (expense), General and administrative - Balancing increase of 80% to $32.6M (expense), Stock-based Compensation in R&D increase from $2.6M to $9.9M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
188 East Blaine Street, Suite 400
SEATTLE
WASHINGTON 98102
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com